Zoetis Inc dividend yield – Zoetis Declares Quarterly Dividend of $0.375 Per Share, Maintaining Previous Yield of 0.93%
February 13, 2023
Trending News ☀️
Zoetis Inc dividend yield – Zoetis Inc ($NYSE:ZTS). recently announced a quarterly dividend of $0.375 per share, maintaining the previous dividend yield of 0.93%. This dividend is payable on June 1, to shareholders of record on April 21 and the ex-dividend date is April 20. Investors interested in learning more about the dividend scorecard, yield chart, and dividend growth offered by Zoetis can visit https://seekingalpha.com/news/3933812-zoetis-inc-declares-0_375-dividend?utm_source=vi.app&utm_medium=referral for more information. Zoetis Inc. is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Zoetis discovers, develops, manufactures, and commercializes veterinary vaccines and medicines, as well as other medical products for both livestock and companion animals. Their portfolio includes products for the prevention, treatment and control of diseases in livestock and companion animals.
In addition to its dividend payments, Zoetis also offers investors other attractive financial benefits such as share repurchases, consistent free cash flow generation, and a strong financial position with significant liquidity. Zoetis is also committed to returning capital to shareholders through share repurchases and dividends. The company’s strong commitment to delivering value back to shareholders is reflected in its robust dividend payout policy. The company’s stable dividend payment history also provides investors with a reliable source of passive income. Overall, Zoetis Inc.’s commitment to providing consistent value back to shareholders through dividends, share repurchases, and free cash flow generation makes it an attractive option for investors looking for steady income and long-term capital appreciation.
Dividends – Zoetis Inc dividend yield
This is the first dividend since the three-year period where it issued an annual dividend per share of 1.23, 1.0, and 0.8 USD respectively. The dividend yields from 2020 to 2022 are estimated to be 0.62%, 0.58%, and 0.57% respectively, with an average dividend yield of 0.59%. This move will also help to ensure that shareholders are able to benefit from the company’s success in the long run. It also shows that Zoetis Inc is confident in its ability to remain profitable despite the volatile economic environment.
This announcement comes shortly after the release of Zoetis Inc’s fourth quarter and full-year 2020 financial results. Zoetis Inc’s management remains committed to delivering value to shareholders through its dividend policy and by taking steps to improve operational efficiency. The company is also focused on developing new products and expanding its global presence in order to drive growth in the future.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zoetis Inc. More…
| Total Revenues | Net Income | Net Margin |
| 8.01k | 2.07k | 26.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zoetis Inc. More…
| Operations | Investing | Financing |
| 1.85k | -587 | -2k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 13.67k | 9.01k | 10 |
Key Ratios Snapshot
Some of the financial key ratios for Zoetis Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.2% | 13.2% | 34.8% |
| FCF Margin | ROE | ROA |
| 15.8% | 37.6% | 12.7% |
Price History
Although the company’s stock opened at $164.8, it closed down by 2.1% at $162.1, compared to the last closing price of $165.6. ZOETIS Inc. is a leading global animal health company that is focused on discovering, developing, manufacturing and commercializing advanced animal health solutions and prescription medicines for livestock and companion animals. The company produces a wide range of products for cattle, swine, poultry, sheep, horses and companion animals, including vaccines, anti-infectives, parasiticides and other pharmaceuticals. With its new dividend announcement, ZOETIS Inc. continues to demonstrate its commitment to providing returns to its shareholders. The company has also acquired a number of businesses in the past year to expand its presence in the animal health industry.
Overall, ZOETIS Inc.’s decision to maintain its quarterly dividend of $0.375 per share is a testament to its commitment to its investors and customers. This dividend payment is an indication of the company’s strong financial performance and its ability to generate consistent returns for its shareholders. Live Quote…
Analysis – Zoetis Inc Intrinsic Value Calculation
GoodWhale has conducted an analysis of ZOETIS INC‘s fundamentals and determined that the fair value of its shares is around $186.4. This valuation was calculated using GoodWhale’s proprietary Valuation Line. Currently, ZOETIS INC stock is traded at $162.1, which is a fair price, but is undervalued by 13.0%. GoodWhale’s Valuation Line takes into account several factors, including the company’s financials, such as revenue, earnings, debt and equity, and the quality of management. The Valuation Line also takes into account macroeconomic factors, such as the market environment, industry trends and political risks. This comprehensive analysis enables GoodWhale to accurately determine the fair value of a company’s shares. In conclusion, GoodWhale’s Valuation Line has determined that ZOETIS INC’s shares are currently undervalued by 13.0%. Investors looking for a sound investment opportunity should consider ZOETIS INC, as the company’s stock is currently trading at a discount compared to its fair value. More…
Peers
Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.
– BioGaia AB ($OTCPK:BIOGY)
Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
– Krka d.d. ($LTS:0HLK)
Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.
Summary
Zoetis Inc., a leading animal health company, recently announced the declaration of its quarterly dividend of $0.375 per share. This dividend amount is the same as that declared in the previous quarter, keeping the yield at 0.93%. This dividend yield indicates the potential for investors to earn regular returns from their investment in Zoetis Inc. The company has consistently maintained a steady dividend payout over the past few years, which is a sign of its strong financial health.
The consistent dividend payout also signals to investors that Zoetis Inc. is committed to rewarding them with regular returns on their investments. Investors should consider the stock as a good long-term investment option due to its strong financials, consistent dividend payouts, and attractive yield.
